Bifogade filer
SenzaGen receives SEK 0.7m order for GARD®skin from one of the world’s largest pharmaceuticals companies
Kurs & Likviditet
Prenumeration
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
SenzaGen has been selected to test substances from a leading global pharmaceuticals company. Valued at SEK 0.7 million, the project involves testing using SenzaGen’s non-animal skin sensitization test, GARD®skin. The testing will be performed at SenzaGen’s GLP-certified laboratory in Lund, Sweden.
The pharmaceuticals company, which is one of the largest in the world, has global operations with a uniquely wide range of treatment areas. With GARD®skin, the company aims to determine whether new development candidates can cause allergic reactions on the skin.
“We are delighted that one of the largest pharmaceutical companies in the world has chosen to partner with SenzaGen and has decided to test substances with GARD®skin, which once again validates the value of GARD®skin internationally. Our test method provides them with fast and reliable results, making it possible to ensure that their substances cannot cause skin allergies already during the development phase. This project serves as further proof that our innovative technology is highly interesting to leading companies in the pharmaceuticals industry. With this new key order, we are continuing to expand our customer base, adding another world leader to our ranks,” says Peter Nählstedt, CEO of SenzaGen.
SenzaGen’s GARD® test platform is designed for companies looking to improve their testing strategy and enhance the accuracy of their test results while avoiding animal testing.